TY - JOUR
T1 - Mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis
AU - Day, Stephanie
AU - Tselios, Theodore
AU - Androutsou, Maria Eleni
AU - Tapeinou, Anthi
AU - Frilligou, Irene
AU - Stojanovska, Lily
AU - Matsoukas, John
AU - Apostolopoulos, Vasso
N1 - Publisher Copyright:
© 2015 Day, Tselios, Androutsou, Tapeinou, Frilligou, Stojanovska, Matsoukas and Apostolopoulos.
PY - 2015
Y1 - 2015
N2 - Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83-99 (MBP83-99) immunodominant epitope conjugated to reduced mannan via the (KG)5 and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP83-99(F91) and linear MBP83-99(Y91) conjugated to reduced mannan via a (KG)5 linker and cyclic MBP83-99(F91) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials.
AB - Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83-99 (MBP83-99) immunodominant epitope conjugated to reduced mannan via the (KG)5 and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP83-99(F91) and linear MBP83-99(Y91) conjugated to reduced mannan via a (KG)5 linker and cyclic MBP83-99(F91) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials.
KW - Altered peptide ligands
KW - MBP83-99
KW - Mannan
KW - Multiple sclerosis
KW - Myelin basic protein
UR - http://www.scopus.com/inward/record.url?scp=84934278178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934278178&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2015.00136
DO - 10.3389/fimmu.2015.00136
M3 - Article
AN - SCOPUS:84934278178
SN - 1664-3224
VL - 6
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - APR
M1 - 136
ER -